DrugInformations.org

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B® (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006.

More: continued here

No Comments »

Medarex, Inc. (Nasdaq: MEDX) announced that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex’s UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount.

More: continued here

No Comments »

Seattle Genetics, Inc. (Nasdaq:SGEN) announced that it has initiated a phase I clinical trial of SGN-70, a humanized monoclonal antibody targeting CD70 that is being developed as an investigational therapy for autoimmune diseases. The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers.

More: continued here

No Comments »

Karen Evans of Baltimore, Maryland was elected Chair of the Lupus Foundation of America, Inc. (LFA) Board of Directors during the Foundation’s recent Annual Meeting in San Antonio, Texas. Ms. Evans will lead the LFA Board’s strategic initiatives to bring national attention and increased public and private resources to fight lupus, an unpredictable and potentially fatal autoimmune disease. Ms.

More: continued here

No Comments »

Your immune system may have more in common with a Corvette than you thought. When a virus or bacteria enters a human body, the immune system revs up to fight and expel the invader. Once the invader is gone, the body puts on the brakes to stop the immune response. But a new study by Patrick Gaffney, M.D., and Kathy Moser, Ph.D.

More: continued here

No Comments »

The Lupus Foundation of America (LFA) has announced the launch of the Center for Clinical Trials Education (CCTE), a resource for people interested in learning about and joining lupus clinical trials. The initial programs of the CCTE include a Website (www.lupus.

More: continued here

No Comments »

MedImmune announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus). The study is designed to assess the safety and tolerability of the antibody, also known as MEDI-545 in patients with moderately to severely active lupus, despite standard of care.

More: continued here

No Comments »

The Lupus Foundation of America (LFA) has announced the launch of the Center for Clinical Trials Education (CCTE), a resource for people interested in learning about and joining lupus clinical trials. The initial programs of the CCTE include a Website and a series of grassroots community education programs on clinical research offered through the LFA’s network of 38 chapters around the country.

More: continued here

No Comments »

A gene that can cause the heart to become enlarged, greatly increasing the risk of heart attacks and heart failure, has been identified in a new study. A gene that can cause the kidney to become inflamed, which can lead to kidney failure, is also revealed in a parallel discovery.

More: continued here

No Comments »

Human Genome Sciences, Inc.

More: continued here

No Comments »